Hyperthermic intraperitoneal chemotherapy in colorectal cancer
Background: This study evaluated the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer with peritoneal metastases (pmCRC) in a large international data set of patients. Patients and Methods: Patients with pmCRC from 39 centres who underwent cytoreductive surgery with...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universidad Francisco de Vitoria |
| Repositorio: | DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria |
| Idioma: | inglés |
| OAI Identifier: | oai:ddfv.ufv.es:10641/7245 |
| Acceso en línea: | https://hdl.handle.net/10641/7245 |
| Access Level: | acceso abierto |
| Palabra clave: | Surgery SDG 3 - Good Health and Well-being Yes yes |
| id |
ES_6a936e83e9f054db95f4e90a61175ed7 |
|---|---|
| oai_identifier_str |
oai:ddfv.ufv.es:10641/7245 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Hyperthermic intraperitoneal chemotherapy in colorectal cancerFisher, Oliver M.Brown, ChrisEsquivel, JesusLarsen, Stein G.Liauw, WinstonAlzahrani, Nayef A.Morris, David L.Kepenekian, VahanSourrouille, IsabelleDumont, FrédéricTuech, Jean JacquesCeribelli, CéciliaDoussot, BérangerSgarbura, OliviaAlhosni, MohammedQuenet, FrancoisGlehen, OlivierCashin, Peter H.Flatmark, KjerstiGraf, WilhelmTakala, HeikkiLowy, Andrew M.Chua, TerencePelz, JoergBaratti, DarioBaumgartner, Joel M.Berri, RichardBretcha-Boix, PedroDeraco, MarcelloFlores-Ayala, GuillermoGomez-Portilla, AlbertoGonzález-Moreno, SantiagoGoodman, MartinHalkia, EvgeniaKusamura, ShigekiMoller, MeckerPassot, GuillaumePocard, MarcSalti, GeorgeSardi, ArmandoSenthil, MaheswariSpilioitis, JohnTorres-Melero, JuanTuraga, KiranBereder, Jean MarcBernard, Jean LouisBakrin, NaoualCarrère, SébastienCoget, JulienCotte, EddyFacy, OlivierGelli, MaximilianoGilly, François NoëlOrtega-Deballon, PabloRat, PatrickRousset, PascalThibaudeau, EmilieVaudoyer, DelphineSurgerySDG 3 - Good Health and Well-beingYesyesBackground: This study evaluated the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer with peritoneal metastases (pmCRC) in a large international data set of patients. Patients and Methods: Patients with pmCRC from 39 centres who underwent cytoreductive surgery with HIPEC between 1991 and 2018 were selected and compared for the HIPEC protocols received - oxaliplatin-HIPEC versus mitomycin-HIPEC. Following analysis of crude data, propensity-score matching (PSM) and Cox-proportional hazard modelling were performed. Outcomes of interest were overall survival (OS), recurrence-free survival (RFS) and the HIPEC dose-response effects (high versus low dose, dose intensification and double drug protocols) on OS, RFS and 90-day morbidity. Furthermore, the impact of the treatment time period was assessed. Results: Of 2760 patients, 2093 patients were included. Median OS was 43 months (95% c.i. 41 to 46 months) with a median RFS of 12 months (95% c.i. 12 to 13 months). The oxaliplatin-HIPEC group had an OS of 47 months (95% c.i. 42 to 53 months) versus 39 months (95% c.i. 36 to 43 months) in the mitomycin-HIPEC group (P = 0.002), aHR 0.77, 95% c.i. 0.67 to 0.90, P < 0.001. The OS benefit persisted after PSM of the oxaliplatin-HIPEC group and mitomycin-HIPEC group (48 months (95% c.i. 42 to 59 months) versus 40 months (95% c.i. 37 to 44 months)), P < 0.001, aHR 0.78 (95% c.i. 0.65 to 0.94), P = 0.009. Similarly, matched RFS was significantly higher for oxaliplatin-HIPEC versus others (13 months (95% c.i. 12 to 15 months) versus 11 months (95% c.i. 10 to 12 months, P = 0.02)). High-dose mitomycin-HIPEC protocols had similar OS compared to oxaliplatin-HIPEC. HIPEC dose intensification within each protocol resulted in improved survival. Oxaliplatin + irinotecan-HIPEC resulted in the most improved OS (61 months (95% c.i. 51 to 101 months)). Ninety-day mortality in both crude and PSM analysis was worse for mitomycin-HIPEC. There was no change in treatment effect depending on the analysed time period. Conclusions: Oxaliplatin-based HIPEC provided better outcomes compared to mitomycin-based HIPEC. High-dose mitomycin-HIPEC was similar to oxaliplatin-HIPEC. The 90-day mortality difference favours the oxaliplatin-HIPEC group. A trend for dose-response between low- and high-dose HIPEC was reported.Facultad de Medicina20242024-06-0120242024-06-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10641/7245reponame:DDFV. Repositorio Institucional de la Universidad Francisco de Vitoriainstname:Universidad Francisco de VitoriaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddfv.ufv.es:10641/72452026-06-11T12:44:57Z |
| dc.title.none.fl_str_mv |
Hyperthermic intraperitoneal chemotherapy in colorectal cancer |
| title |
Hyperthermic intraperitoneal chemotherapy in colorectal cancer |
| spellingShingle |
Hyperthermic intraperitoneal chemotherapy in colorectal cancer Fisher, Oliver M. Surgery SDG 3 - Good Health and Well-being Yes yes |
| title_short |
Hyperthermic intraperitoneal chemotherapy in colorectal cancer |
| title_full |
Hyperthermic intraperitoneal chemotherapy in colorectal cancer |
| title_fullStr |
Hyperthermic intraperitoneal chemotherapy in colorectal cancer |
| title_full_unstemmed |
Hyperthermic intraperitoneal chemotherapy in colorectal cancer |
| title_sort |
Hyperthermic intraperitoneal chemotherapy in colorectal cancer |
| dc.creator.none.fl_str_mv |
Fisher, Oliver M. Brown, Chris Esquivel, Jesus Larsen, Stein G. Liauw, Winston Alzahrani, Nayef A. Morris, David L. Kepenekian, Vahan Sourrouille, Isabelle Dumont, Frédéric Tuech, Jean Jacques Ceribelli, Cécilia Doussot, Béranger Sgarbura, Olivia Alhosni, Mohammed Quenet, Francois Glehen, Olivier Cashin, Peter H. Flatmark, Kjersti Graf, Wilhelm Takala, Heikki Lowy, Andrew M. Chua, Terence Pelz, Joerg Baratti, Dario Baumgartner, Joel M. Berri, Richard Bretcha-Boix, Pedro Deraco, Marcello Flores-Ayala, Guillermo Gomez-Portilla, Alberto González-Moreno, Santiago Goodman, Martin Halkia, Evgenia Kusamura, Shigeki Moller, Mecker Passot, Guillaume Pocard, Marc Salti, George Sardi, Armando Senthil, Maheswari Spilioitis, John Torres-Melero, Juan Turaga, Kiran Bereder, Jean Marc Bernard, Jean Louis Bakrin, Naoual Carrère, Sébastien Coget, Julien Cotte, Eddy Facy, Olivier Gelli, Maximiliano Gilly, François Noël Ortega-Deballon, Pablo Rat, Patrick Rousset, Pascal Thibaudeau, Emilie Vaudoyer, Delphine |
| author |
Fisher, Oliver M. |
| author_facet |
Fisher, Oliver M. Brown, Chris Esquivel, Jesus Larsen, Stein G. Liauw, Winston Alzahrani, Nayef A. Morris, David L. Kepenekian, Vahan Sourrouille, Isabelle Dumont, Frédéric Tuech, Jean Jacques Ceribelli, Cécilia Doussot, Béranger Sgarbura, Olivia Alhosni, Mohammed Quenet, Francois Glehen, Olivier Cashin, Peter H. Flatmark, Kjersti Graf, Wilhelm Takala, Heikki Lowy, Andrew M. Chua, Terence Pelz, Joerg Baratti, Dario Baumgartner, Joel M. Berri, Richard Bretcha-Boix, Pedro Deraco, Marcello Flores-Ayala, Guillermo Gomez-Portilla, Alberto González-Moreno, Santiago Goodman, Martin Halkia, Evgenia Kusamura, Shigeki Moller, Mecker Passot, Guillaume Pocard, Marc Salti, George Sardi, Armando Senthil, Maheswari Spilioitis, John Torres-Melero, Juan Turaga, Kiran Bereder, Jean Marc Bernard, Jean Louis Bakrin, Naoual Carrère, Sébastien Coget, Julien Cotte, Eddy Facy, Olivier Gelli, Maximiliano Gilly, François Noël Ortega-Deballon, Pablo Rat, Patrick Rousset, Pascal Thibaudeau, Emilie Vaudoyer, Delphine |
| author_role |
author |
| author2 |
Brown, Chris Esquivel, Jesus Larsen, Stein G. Liauw, Winston Alzahrani, Nayef A. Morris, David L. Kepenekian, Vahan Sourrouille, Isabelle Dumont, Frédéric Tuech, Jean Jacques Ceribelli, Cécilia Doussot, Béranger Sgarbura, Olivia Alhosni, Mohammed Quenet, Francois Glehen, Olivier Cashin, Peter H. Flatmark, Kjersti Graf, Wilhelm Takala, Heikki Lowy, Andrew M. Chua, Terence Pelz, Joerg Baratti, Dario Baumgartner, Joel M. Berri, Richard Bretcha-Boix, Pedro Deraco, Marcello Flores-Ayala, Guillermo Gomez-Portilla, Alberto González-Moreno, Santiago Goodman, Martin Halkia, Evgenia Kusamura, Shigeki Moller, Mecker Passot, Guillaume Pocard, Marc Salti, George Sardi, Armando Senthil, Maheswari Spilioitis, John Torres-Melero, Juan Turaga, Kiran Bereder, Jean Marc Bernard, Jean Louis Bakrin, Naoual Carrère, Sébastien Coget, Julien Cotte, Eddy Facy, Olivier Gelli, Maximiliano Gilly, François Noël Ortega-Deballon, Pablo Rat, Patrick Rousset, Pascal Thibaudeau, Emilie Vaudoyer, Delphine |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Facultad de Medicina |
| dc.subject.none.fl_str_mv |
Surgery SDG 3 - Good Health and Well-being Yes yes |
| topic |
Surgery SDG 3 - Good Health and Well-being Yes yes |
| description |
Background: This study evaluated the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer with peritoneal metastases (pmCRC) in a large international data set of patients. Patients and Methods: Patients with pmCRC from 39 centres who underwent cytoreductive surgery with HIPEC between 1991 and 2018 were selected and compared for the HIPEC protocols received - oxaliplatin-HIPEC versus mitomycin-HIPEC. Following analysis of crude data, propensity-score matching (PSM) and Cox-proportional hazard modelling were performed. Outcomes of interest were overall survival (OS), recurrence-free survival (RFS) and the HIPEC dose-response effects (high versus low dose, dose intensification and double drug protocols) on OS, RFS and 90-day morbidity. Furthermore, the impact of the treatment time period was assessed. Results: Of 2760 patients, 2093 patients were included. Median OS was 43 months (95% c.i. 41 to 46 months) with a median RFS of 12 months (95% c.i. 12 to 13 months). The oxaliplatin-HIPEC group had an OS of 47 months (95% c.i. 42 to 53 months) versus 39 months (95% c.i. 36 to 43 months) in the mitomycin-HIPEC group (P = 0.002), aHR 0.77, 95% c.i. 0.67 to 0.90, P < 0.001. The OS benefit persisted after PSM of the oxaliplatin-HIPEC group and mitomycin-HIPEC group (48 months (95% c.i. 42 to 59 months) versus 40 months (95% c.i. 37 to 44 months)), P < 0.001, aHR 0.78 (95% c.i. 0.65 to 0.94), P = 0.009. Similarly, matched RFS was significantly higher for oxaliplatin-HIPEC versus others (13 months (95% c.i. 12 to 15 months) versus 11 months (95% c.i. 10 to 12 months, P = 0.02)). High-dose mitomycin-HIPEC protocols had similar OS compared to oxaliplatin-HIPEC. HIPEC dose intensification within each protocol resulted in improved survival. Oxaliplatin + irinotecan-HIPEC resulted in the most improved OS (61 months (95% c.i. 51 to 101 months)). Ninety-day mortality in both crude and PSM analysis was worse for mitomycin-HIPEC. There was no change in treatment effect depending on the analysed time period. Conclusions: Oxaliplatin-based HIPEC provided better outcomes compared to mitomycin-based HIPEC. High-dose mitomycin-HIPEC was similar to oxaliplatin-HIPEC. The 90-day mortality difference favours the oxaliplatin-HIPEC group. A trend for dose-response between low- and high-dose HIPEC was reported. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024 2024-06-01 2024 2024-06-01 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/10641/7245 |
| url |
https://hdl.handle.net/10641/7245 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria instname:Universidad Francisco de Vitoria |
| instname_str |
Universidad Francisco de Vitoria |
| reponame_str |
DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria |
| collection |
DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869410122231447552 |
| score |
15,812455 |